4.28
4 D Molecular Therapeutics Inc stock is traded at $4.28, with a volume of 449.73K.
It is up +0.94% in the last 24 hours and down -9.32% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$4.24
Open:
$4.24
24h Volume:
449.73K
Relative Volume:
0.52
Market Cap:
$198.17M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-1.609
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
+3.38%
1M Performance:
-9.32%
6M Performance:
-73.66%
1Y Performance:
-85.44%
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FDMT
4 D Molecular Therapeutics Inc
|
4.28 | 198.17M | 20.72M | -100.84M | -78.56M | -2.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Nov-21-24 | Initiated | Morgan Stanley | Underweight |
Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Apr-15-24 | Initiated | Barclays | Overweight |
Feb-07-24 | Resumed | Goldman | Buy |
Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
Nov-18-22 | Initiated | H.C. Wainwright | Buy |
Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jun-22-22 | Initiated | Jefferies | Buy |
Jan-04-22 | Initiated | SVB Leerink | Outperform |
Jan-05-21 | Initiated | BofA Securities | Buy |
Jan-05-21 | Initiated | Evercore ISI | Outperform |
Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World
4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com
4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire
FDMT4D Molecular Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World
FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World
Analysts Issue Forecasts for FDMT Q1 Earnings - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan Capital - Defense World
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Deeper Dive: Understanding 4D Molecular Therapeutics Inc (FDMT) Through its Various Ratios - The Dwinnex
4D Molecular price target lowered to $35 from $39 at RBC Capital - Yahoo Finance
Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating - Marketscreener.com
4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank of Canada - Defense World
Moderna (NASDAQ:MRNA) and 4D Molecular Therapeutics (NASDAQ:FDMT) Head to Head Review - Defense World
4D Molecular price target lowered to $28 from $30 at Chardan - TipRanks
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics - Benzinga
RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk - Marketscreener.com
4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance UK
4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position - TipRanks
FDMT stock touches 52-week low at $4.4 amid sharp annual decline - Investing.com Australia
4D Molecular Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
4D Molecular Therapeutics, Inc. SEC 10-K Report - TradingView
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics Reports Positive Clinical Data for 4D-150 in Wet AMD and DME, Outlines Strategic Pipeline and Financial Position - Nasdaq
Can 4DMT's $505M Cash Runway and Promising Eye Disease Data Overcome Rising Losses? - StockTitan
Spotlight On February 2025's Promising Penny Stocks - Simply Wall St
4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday - Defense World
4D Molecular Therapeutics, Inc. (FDMT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $32.13 - Defense World
4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
4D Molecular's March Investor Showcase: What These Two Major Conference Appearances Signal - StockTitan
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha
4D Molecular Therapeutics' SWOT analysis: gene therapy firm's stock faces durability test - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $30.00 Price Target at Chardan Capital - MarketBeat
Peapod Lane Capital LLC Purchases New Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Jefferies cuts 4D Molecular Therapeutics target to $40 - MSN
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
FDMT stock touches 52-week low at $4.42 amid sharp annual decline - Investing.com India
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $30.00 at Chardan Capital - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - PR Newswire
Gene Therapy In CNS Disorder Treatment Market Size Report 2032 | - openPR
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):